COX-2 expression positively correlates with PD-L1 expression in human melanoma cells-Reference-Cited by-同舟云学术

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Published:2017-02-23 Issue:1 Volume:15 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Botti Gerardo,Fratangelo Federica,Cerrone Margherita,Liguori Giuseppina,Cantile Monica,Anniciello Anna Maria,Scala Stefania,D’Alterio Crescenzo,Trimarco Chiara,Ianaro Angela,Cirino Giuseppe,Caracò Corrado,Colombino Maria,Palmieri Giuseppe,Pepe Stefano,Ascierto Paolo Antonio,Sabbatino Francesco,Scognamiglio Giosuè

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-017-1150-7.pdf

Reference62 articles.

1. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer. 2016;53:125–34.

2. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32.

3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.

4. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.

5. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-08

2. A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE₂ Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy;Advanced Healthcare Materials;2024-05-05

3. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy;Rheumatic Disease Clinics of North America;2024-05

4. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1;Cancers;2024-03-21

5. Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors;Veterinary Sciences;2024-02-07